格隆汇1月20日丨创新医疗(002173.SZ)公布，阮光寅董事持有公司股份1,540,987股，占公司总股本的 0.3492%，计划在本公告披露之日起15个交易日后的三个月内，以集中竞价交易方式减持本公司股份， 合计减持数量不超过385,200股，即不超过公司总股本的0.0873%。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-003 创新医疗管理股份有限公司 关于董事减持股份的预披露公告 阮光寅董事保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 创新医疗管理股份有限公司（以下简称"公司"）阮光寅董事持有公司股份 1,540,987 股，占公司总股本的 0.3492%，计划在本公告披露之日起 15 个交易日 后的三个月内，以集中竞价交易方式减持本公司股份，合计减持数量不超过 385,200 股，即不超过公司总股本的 0.0873%。 公司于近日收到阮光寅董事提交的《股份减持计划告知函》。根据《上市公 司股东减持股份管理暂行办法》、《上市公司董事、监事和高级管理人员所持本公 司股份及其变动管理规则》、《深圳证券交易所上市公司自律监管指引第 18 号— —股东及董事、监事、高级管理人员减持股份》等有关规定，现将具体内容公告 如下： 一、股东的基本情况 1、股东名称：阮光寅 2、股东持有股份的数量、占公司总股本的比例：截至本公告披露日，阮光 寅持有公司股份 1, ...

创新医疗公告，阮光寅董事持有公司股份154.1万股，占公司总股本0.3492%，拟自公告披露后15个交易 日后的三个月内，以集中竞价方式减持不超过38.52万股，占公司总股本0.0873%。股份来源为公司首次 公开发行前已发行的股份（含因资本公积金转增股本相应增加的股份）。如公司发生送股、资本公积金 转增股本、配股等除权除息事项，减持数量将相应调整，减持价格按市场价格确定。 ...

Group 1 - The core viewpoint of the news is that Innovation Medical's stock has experienced significant fluctuations, with a year-to-date increase of 33.66% but a recent decline of 18.11% over the past five trading days [1] - As of January 20, the stock price was 28.75 yuan per share, with a total market capitalization of 12.687 billion yuan [1] - The company has seen a net outflow of 14.05 million yuan in principal funds, with large orders showing a buy of 57.736 million yuan and a sell of 72.818 million yuan [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased by 58.75% to 130,200, while the average circulating shares per person decreased by 37.01% to 3,196 shares [2] - For the period from January to September 2025, the company reported a revenue of 597 million yuan, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders increased by 116.97% to 4.7244 million yuan [2]

证券之星消息，截至2026年1月16日收盘，创新医疗(002173)报收于29.2元，下跌8.18%，换手率 24.68%，成交量102.74万手，成交额31.13亿元。 1月16日的资金流向数据方面，主力资金净流出2.52亿元，占总成交额8.11%，游资资金净流出1.7亿 元，占总成交额5.45%，散户资金净流入4.22亿元，占总成交额13.56%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。创新医疗（002173）主营业务：提供医疗服务。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单 ...

Group 1 - The core point of the article highlights that Innovation Medical (002173) experienced a significant decline in stock price, closing at 29.2 yuan on January 16, down 8.18% [1][2] - The stock has seen a continuous drop for four consecutive days, with two of the last five trading days recording a decline of over 5% [2] - In the first ten trading days, the stock price had an overall increase of 35.44%, despite the recent downturn [2] Group 2 - On January 16, the stock recorded a trading volume of 1.03 billion yuan, with a turnover rate of 24.68% and a total transaction volume of 1.0274 million hands [1] - During the same day, the main funds experienced a net outflow of 2.52 billion yuan, while retail investors saw a net inflow of 4.22 billion yuan [1] - Over the first ten trading days, the main funds had a cumulative net outflow of 9.42 billion yuan, while the financing balance increased by 3.25 billion yuan [1]

Core Viewpoint - The brain-computer interface (BCI) sector in the A-share market has shown significant activity at the beginning of 2026, with a cumulative increase of 18.04% in the BCI theme index as of January 16, 2026, indicating a strong interest and potential for commercialization in this emerging industry [2][4]. Industry Overview - The BCI industry is projected to reach a market size of trillions, transitioning from laboratory research to commercial applications, driven by advancements in technology and supportive government policies [3]. - The Ministry of Industry and Information Technology and other departments have emphasized the importance of BCI in their strategic plans, including its inclusion in the "14th Five-Year Plan" for future industrial development [3]. Market Performance - As of January 16, 2026, the total market capitalization of 26 listed companies in the BCI sector has increased by approximately 108.7 billion yuan over ten trading days [8]. - Notable companies like Innovation Medical and Meihua Medical have experienced significant stock price fluctuations, reflecting the volatile nature of the market and investor sentiment towards BCI technologies [5][7]. Company Developments - Innovation Medical's subsidiary, Boling Brain Machine Technology, has launched products aimed at rehabilitation for stroke patients, although it reported operating losses of 6.6 million yuan and 8.66 million yuan in 2023 and 2024, respectively [6]. - Meihua Medical, a leader in cochlear implants, is actively collaborating with BCI clients to facilitate the transition from laboratory research to commercial production, highlighting the interconnectedness of BCI and existing medical technologies [7]. Strategic Collaborations - Companies like Yahui Long and Shenzhen Brain Machine Star Chain Technology have entered strategic partnerships to develop BCI-related products, aiming to enhance diagnostic and treatment capabilities in central nervous system diseases [9]. - Aipeng Medical is also expanding its business into BCI applications, focusing on pain management and sleep disorders, indicating a broader trend of diversification within the medical device sector [9]. Technical Insights - The core technological barriers in the BCI industry are concentrated in the upstream supply chain, including hardware components and surgical techniques, with significant potential for growth in domestic market penetration and localization [10].

Core Viewpoint - The Shandong Provincial Government has issued a policy document aimed at deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry, marking a significant step in balancing drug safety and industrial growth [6][11]. Group 1: Policy Implementation - The document outlines 29 measures across six key areas to enhance the innovation and development of the pharmaceutical industry [7]. - It emphasizes the importance of drug and medical devices as critical goods related to public health and safety, as well as economic development [4]. Group 2: Key Measures - Strengthening the cultivation of pharmaceutical innovation by supporting cutting-edge technology, enhancing innovation platforms, and promoting the transformation of innovative drugs and devices [7]. - Optimizing the clinical trial ecosystem by encouraging medical institutions to undertake trials, improving ethical review efficiency, and applying AI technology [8]. - Deepening review and approval reforms, including proactive engagement with national drug regulatory bodies and supporting segmented production of drugs [9][10]. Group 3: Industry Growth and Internationalization - Promoting the international development of the industry through targeted investment attraction and enhancing international cooperation [9]. - Encouraging the clinical promotion and use of innovative products by establishing product directories and improving insurance payment mechanisms [8]. Group 4: Quality Supervision - Strengthening quality supervision throughout the entire process, ensuring corporate responsibility, and enhancing smart regulatory capabilities [10][13]. - Implementing a comprehensive regulatory framework to ensure drug safety and efficacy, utilizing big data and AI for monitoring [13]. Group 5: Collaborative Efforts - Enhancing collaboration among various departments such as technology, health, and drug regulation to create a seamless connection between clinical trials, usage, and insurance coverage [12]. - Establishing a mechanism for mutual recognition of ethical reviews in multi-center clinical trials to reduce costs and time for enterprises [12]. Group 6: Future Directions - The Shandong Provincial Drug Administration will work with relevant departments to ensure drug safety and support the high-quality development of the pharmaceutical industry [13].

Group 1 - The core viewpoint of the news is that Innovation Medical has experienced significant stock price fluctuations, with a year-to-date increase of 44.86% but a recent decline of 10.05% over the last five trading days [1] - As of January 16, the stock price was reported at 31.16 yuan per share, with a total market capitalization of 13.75 billion yuan [1] - The company has seen a net outflow of main funds amounting to 6.84 million yuan, with significant trading activity reflected in the large buy and sell orders [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services [2] - The company reported a revenue of 597 million yuan for the period from January to September 2025, showing a year-on-year decrease of 2.11%, while net profit increased by 116.97% to 4.72 million yuan [2] - The number of shareholders has increased to 130,200, a rise of 58.75%, while the average circulating shares per person decreased by 37.01% [2]

Group 1 - The construction of a "super factory" by Brain Tiger Technology in Jiangxi marks a significant transition from laboratory research to large-scale production in the brain-computer interface (BCI) sector, aiming for stable supply of tens of thousands of units [1][6] - The factory will produce China's first and the world's second fully implanted, fully wireless, and fully functional BCI system, highlighting the growing market potential across healthcare, consumer electronics, and military applications [1][6] - Global developments include Neuralink's announcement to start large-scale production of BCI devices by 2026, indicating a shift from clinical validation to industrialization [1][6] Group 2 - The Chinese government is actively promoting the BCI industry, with a policy document aiming for breakthroughs in key technologies by 2027 and a robust industry system by 2030 [2][7] - The "14th Five-Year Plan" identifies BCI as a future industry requiring strategic development, with various regions setting clear goals for BCI technology and product applications [2][7] - Successful surgeries have been performed on high-level paraplegics using BCI technology, enabling patients to control devices and participate in rehabilitation and employment activities [2][7] Group 3 - The BCI sector has attracted significant investment, with the A-share market showing a cumulative increase of over 20% since 2026, and several stocks rising more than 50% [3][8] - As of January 13, 2023, the financing balance for 26 BCI-related stocks reached nearly 25.5 billion yuan, a 15% increase from the previous year, with many stocks seeing substantial increases in their financing [3][8] - Notable companies include Meihua Medical, with a financing balance of 470 million yuan and a 255% increase, and Innovation Medical, with a balance of 744 million yuan and a 105% increase [3][8][9]